Glycemic control and all-cause mortality risk in type 1 diabetes patients: The EURODIAB prospective complications study

Journal of Clinical Endocrinology and Metabolism

Volumn 99, Issue 3, 2014, Pages 800-807

  Schoenaker, Danielle A J M ^a   Simon, Dominique ^b,c   Chaturvedi, Nish ^d   Fuller, John H ^e   Soedamah Muthu, Sabita S ^f  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c CENTRE FOR RESEARCH IN EPIDEMIOLOGY AND POPULATION HEALTH   (France)

^d NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f WAGENINGEN UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN A1C;

ADOLESCENT; ADULT; AGE; ARTICLE; COHORT ANALYSIS; DISEASE ASSOCIATION; ETHNICITY; EUROPE; EUROPEAN; FEMALE; FOLLOW UP; GENDER; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; REFERENCE VALUE; RISK ASSESSMENT;

ADOLESCENT; ADULT; BLOOD GLUCOSE; CAUSE OF DEATH; COHORT STUDIES; DIABETES MELLITUS, TYPE 1; EUROPE; FEMALE; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84895787229     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2013-2824     Document Type: Article

References (30)

1. Soedamah-Muthu SS, Fuller JH, Mulnier HE, Raleigh VS, Lawrenson RA, ColhounHM. All-cause mortality rates in patients with type 1 diabetes mellitus compared with a non-diabetic population from the UK general practice research database, 1992-1999. Diabetologia. 2006;49(4):660-666. (Pubitemid 43357538)
2. American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care. 2012;34(suppl 1):S11-S63.
3. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559.
4. Buehler AM, Cavalcanti AB, Berwanger O, et al. Effect of tight blood glucose control versus conventional control in patients with type 2 diabetes mellitus: a systematic review with meta-analysis of randomized controlled trials. Cardiovasc Ther. 2011;31(3):147-160.
5. Hemmingsen B, Lund SS, Gluud C, et al. Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials. BMJ. 2011;343:d6898.
6. Currie CJ, Peters JR, Tynan A, et al. Survival as a function of HbA1c in people with type 2 diabetes: a retrospective cohort study. Lancet. 2010;375(9713):481-489.
7. Dahl-Jørgensen K, Larsen J, Hanssen K. Atherosclerosis in childhood and adolescent type 1 diabetes: early disease, early treatment? Diabetologia. 2005;48(8):1445-1453. (Pubitemid 41175493)
8. Stephenson J, Fuller JH, Eurodiab Complications Study Group. Microvascular and acute complications in IDDM patients: the EURODIAB IDDM Complications Study. Diabetologia. 1994; 37(3):278 -285.
9. Chaturvedi N, Bandinelli S, Mangili R, Penno G, Rottiers RE, Fuller JH. Microalbuminuria in type 1 diabetes: rates, risk factors and glycemic threshold. Kidney Int. 2001;60(1):219-227. (Pubitemid 32587557)
10. Hanas R, John G. 2010 Consensus Statement on the Worldwide Standardization of the Hemoglobin A1C Measurement. Diabetes Care. 2010;33(8):1903-1904.
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18(6):499-502.
12. Soedamah-Muthu SS, Chaturvedi N, Witte DR, Stevens LK, Porta M, Fuller JH. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: The EURODIAB Prospective Complications Study (PCS). Diabetes Care. 2008;31(7):1360-1366.
13. Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis. New York: Springer-Varlag New York, Inc; 2001.
14. Akaike H. A new look at the statistical model identification. IEEE Trans Automat Contr. 1974;19(6):716-723.
15. Tielemans SM, Soedamah-Muthu SS, De Neve M, et al. Association of physical activity with all-cause mortality and incident and prevalent cardiovascular diseaseamongpatients with type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetologia. 2012; 56(1):82-91.
16. Heinzl H, Kaider A. Manual for the SAS-Macro RCS. SAS Institute Inc; 2007. Available at: http://cemsiis.meduniwien.ac.at/kb/wf/software/statistische- software/rcs/.
17. Huang ES, Liu JY, Moffet HH, John PM, Karter AJ. Glycemic control, complications, and death in older diabetic patients. Diabetes Care. 2011;34(6):1329-1336.
18. Riddle MC, Karl DM. Individualizing targets and tactics for high-risk patients with type 2 diabetes: practical lessons from ACCORD and other cardiovascular trials. Diabetes Care. 2012;35(10):2100-2107.
19. Riddle MC, Ambrosius WT, Brillon DJ, et al. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD Trial. Diabetes Care. 2010;33(5):983-990.
20. Zoungas S, Chalmers J, Ninomiya T, et al. Association of HbA1c levels with vascular complications and death in patients with type 2 diabetes: evidence of glycaemic thresholds. Diabetologia. 2012; 55(3):636-643.
21. Duckworth W, Abraira C, Moritz T, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129-139.
22. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977-986.
23. Genuth S, Backlund J-YC, Bayless M, et al. Effects of prior intensive versus conventional therapy and history of glycemia on cardiac function in type 1 diabetes in the DCCT/EDIC. Diabetes. 2013;62(10): 3561-3569.
24. Nathan D, Cleary P, Backlund J, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353(25):2643-2653. (Pubitemid 41817713)
25. Rutter M. Low HbA1c and mortality: causation and confounding. Diabetologia. 2012;55(9):2307-2311.
26. Greenfield S, Billimek J, Pellegrini F, et al. Comorbidity affects the relationship between glycemic control and cardiovascular outcomes in diabetes: a cohort study. Ann Int Med. 2009;151(12):854-860.
27. Tsujimoto T, Yamamoto-Honda R, Kajio H, et al. Vital signs, QT prolongation, and newly diagnosed cardiovascular disease during severe hypoglycemia in type 1 and type 2 diabetic patients. Diabetes Care. 2014;37(1):217-225.
28. Gallagher EJ, Le Roith D, Bloomgarden Z. Review of hemoglobin A1c in the management of diabetes. J Diabetes. 2009;1(1):9 -17.
29. Lipska KJ, Warton EM, Huang ES, et al. HbA1c and risk of severe hypoglycemia in type 2 diabetes: the Diabetes and Aging Study. Diabetes Care. 2013;36(11):3535-3542.
30. Gruden G, Barutta F, Chaturvedi N, et al. Severe hypoglycemia and cardiovascular disease incidence in type 1 diabetes: the EURODIAB Prospective Complications Study. Diabetes Care. 2012; 35(7):1598 -1604.